1. Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study
- Author
-
Steven D Nathan, Hilary M DuBrock, Victor F Tapson, Aaron B Waxman, Karim El-Kersh, Jason Weatherald, Eric Shen, Chunqin Deng, Steven J Cassady, Rahul G Argula, Franz P Rischard, James Tarver, Deborah J Levine, and Manisit Das
- Subjects
Medicine ,Diseases of the respiratory system ,RC705-779 - Abstract
Background Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) to improve exercise capacity. This post hoc analysis evaluated clinical worsening and PH-ILD exacerbations from the 16-week INCREASE study and change in 6-minute walking distance (6MWD) in the INCREASE open-label extension (OLE) in patients with less severe haemodynamics.Methods Patients were stratified by baseline pulmonary vascular resistance (PVR) of 5 WU. Exacerbations of underlying lung disease, clinical worsening and change in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in INCREASE were evaluated. For the OLE, patients previously assigned to placebo were considered to have a 16-week treatment delay. 6MWD and clinical events in the OLE were evaluated by PVR subgroup.Results Of the 326 patients enrolled in INCREASE, patients with less severe haemodynamics receiving iTre had fewer exacerbations of underlying lung disease and clinical worsening events. This was supported by the Bayesian analysis of the risk of disease progression (HR
- Published
- 2024
- Full Text
- View/download PDF